Bioregenx (BRGX) Capital Expenditures (2024 - 2025)

Bioregenx (BRGX) recorded quarterly Capital Expenditures of $3057.0 in Q4 2025, down 49.05% quarter-over-quarter from $6000.0 in Q3 2025.

Bioregenx (BRGX) Capital Expenditures (2024 - 2025) Analysis & Trends

Bioregenx's Capital Expenditures history runs 2 years deep, the most recent figure standing at $3057.0 for Q4 2025.

In Q4 2025, Capital Expenditures changed N/A year-over-year to $3057.0; the TTM figure through Dec 2025 stood at $9057.0 (down 95.22% YoY), while the FY2025 annual figure was $9057.0, down 95.22% from the prior year.
Capital Expenditures was $3057.0 for Q4 2025 at Bioregenx, down from $6000.0 in the prior quarter.
In the past five years, Capital Expenditures ranged from a high of $189390.0 in Q1 2024 to a low of $3057.0 in Q4 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Capex (Qtr)
1	Veeva Systems	24.83 Bn	17.52 Bn	662.02 Mn	1.75 Mn
2	BrightSpring Health Services	13.57 Bn	12.69 Bn	482.22 Mn	3.67 Mn
3	Healthequity	7.20 Bn	6.93 Bn	256.31 Mn	15.93 Mn
4	Hinge Health	5.42 Bn	5.11 Bn	154.23 Mn	28,000.00
5	10x Genomics	4.46 Bn	3.92 Bn	106.18 Mn	118,000.00
6	Doximity	3.81 Bn	3.06 Bn	125.97 Mn	2.25 Mn
7	Waystar Holding	3.52 Bn	3.36 Bn	268.04 Mn	15.33 Mn
8	Privia Health	2.94 Bn	2.57 Bn	595.71 Mn	-
9	Omnicell	1.76 Bn	1.59 Bn	140.36 Mn	12.44 Mn
10	Bioregenx	-	-	348,288.00	-

Download Data